Building Strategic Academia-Industry Partnerships Across the Radiopharmaceutical Lifecycle: Lessons from UHN’s Integrated Theranostics Ecosystem
11:30 am - Tuesday 1st December 2026
- Building strategic partnerships across the radiopharmaceutical lifecycle – from discovery research and preclinical development through clinical trials, manufacturing, commercialization, and patient care.
- Creating integrated infrastructure that accelerates translation – leveraging capabilities such as multi-centre imaging trials, translational research platforms, radiopharmaceutical production, and Phase 0 clinical development to move innovations from concept to clinic more efficiently.
- Translating innovation into clinical and commercial impact through collaborative models – highlighting lessons learned from industry partnerships that support clinical validation, evidence generation, commercialization, and the adoption of novel radiopharmaceutical therapies. The UHN 177Lu-DOTATATE experience illustrates how academic research, clinical trials, dosimetry development, and commercialization can collectively advance new therapies from concept to patient care.
- Building a collaborative radiopharmaceutical ecosystem – fostering ongoing dialogue, education, and advocacy among academia, industry, government, and healthcare providers to support innovation and patient access.
